Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections.
Previous vaccine strategies targeted the bacterium’s primary toxins, according to a Feb. 18 system news release. Though this strategy protected against severe infection, it did not reduce the bacterial burden.
Vanderbilt’s approach is administered to the mucosal lining of the colon and provides long-term protection against illness, death, tissue damage and infection recurrence. Animals with C. diff infections at 60 and 200 days after the final vaccine dose were protected against illness and death. They also cleared both vegetative and spore forms of the infection.
The findings were published Feb. 18 in Nature.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
